A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.


Updates from The Motley Fool

Latest updates on Dynavax Technologies from Fool.com.  The Fool has written over 100 articles on Dynavax Technologies.
3 Biotech Stocks to Buy in April

On the hunt for a good biotech stock to buy in April? Our Motley Fool healthcare contributors thi...

5 Top Stocks to Buy In November

Our contributors weigh in across sectors on SeaWorld, General Motors, Huntington Ingalls, Dynavax...



Stock Performance

View Interactive DVAX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Dynavax Technologies.
Current Price: $9.55
Prev Close: $9.55
Open: $9.65
Bid: $9.55
Ask: $9.60
Day's Range: $9.50 - $9.85
52wk Range: $3.20 - $17.50
Volume: 596,906
Avg Vol 1,771,913
Market Cap: $523M
P/E (ttm): -3.39
EPS (ttm): ($2.82)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Dynavax Technologies.
CAPS Rating 3 out of 5
 
202 Outperform
13 Underperform
CAPS All Stars
 
36 Outperform
5 Underperform

How do you think Dynavax Technologies will perform against the market?



You pick for Dynavax Technologies is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Eddie Gray, CEO

76% Approve

Based on 8 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Dynavax Technologies.

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers